IDEXX Laboratories (IDXX) to Release Quarterly Earnings on Wednesday

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) will be posting its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect IDEXX Laboratories to post earnings of $2.68 per share for the quarter. IDEXX Laboratories has set its FY24 guidance at $10.84-11.33 EPS and its FY 2024 guidance at 10.840-11.330 EPS.Parties that wish to listen to the company's conference call can do so using this link.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 EPS. On average, analysts expect IDEXX Laboratories to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

IDEXX Laboratories Stock Up 0.1 %

Shares of NASDAQ IDXX traded up $0.46 during mid-day trading on Wednesday, reaching $494.26. 493,029 shares of the company traded hands, compared to its average volume of 431,297. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a market cap of $41.05 billion, a PE ratio of 49.03, a price-to-earnings-growth ratio of 3.69 and a beta of 1.26. The company's fifty day moving average is $535.07 and its two-hundred day moving average is $510.61. IDEXX Laboratories has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

Analyst Ratings Changes

IDXX has been the topic of a number of analyst reports. Barclays increased their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a report on Tuesday, February 6th. JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a report on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. William Blair reaffirmed an "outperform" rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Finally, The Goldman Sachs Group lifted their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research note on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $591.50.

Insider Activity

In other news, CFO Brian P. Mckeon sold 23,326 shares of the business's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company's stock, valued at $45,377,624.67. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian P. Mckeon sold 23,326 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock worth $24,871,960 over the last three months. Corporate insiders own 2.18% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.